Cortendo AB is a biopharmaceutical company headquartered in Göteborg, Sweden. Its stock is publicly traded on the NOTC-A-list (OTC) in Norway. Cortendo is a pioneer in the field of cortisol inhibition and has completed early clinical trials in patients with Type 2 diabetes. It was founded in 1996 by Dr. Per Marin (photo to the left), who remains a Scientific Advisor to Cortendo.  The development of the lead drug candidate NormoCort (COR003), the 2S,4R-enantiomer of ketoconazole, has been re-directed to Cushing’s Syndrome.

The company primarily focuses its resources where the path to commercialization or partnerships is clear and relatively near-term. Strategically, Cortendo’s business model is to commercialize relevant opportunities in the United States while partnering its assets ex-US. Backed by a highly experienced leadership team Cortendo has plans to continue to implement its pipeline expansion efforts in osteoarthritis and diabetes, as well as other near term revenue opportunities.